. >> we mentioned health care, bristol myers. 27th, i think the stock rallies in earnings. >> bonawyn >> tight labor market, tight housing market, dhi. >> courtney? >> the one we agreed on with housing. you stole my final trade i'm going with itv you want to look the owl your home builders here. >> steve >> gray scale trust. this one looked like it was ready to pop to me mid june. started to pop i think it has more in it. going to be back and forth ultimately i think it gets to about 20 bucks >> did not see that coming that's going to do it for us on "fast money" but don't go anywhere, because "options action" is next. ♪ ♪ the biggest ideas inspire new ones. 30 years ago, state street created an etf that inspired the world to invest differently. it still does. what can you do with spy? ♪ ♪ this is american infrastructure, a prime target for cyberattacks. but the same ai-powered security that protects all of google also defends these services for everyone who lives here. ♪ >>> right now on at o.a. investors digest early results from banks how options traders handicapping the action we'

and is nothing but congressional overreach, the same argument made by drug lou makers merck and bristol-myersdministration says it will defend that provision that aims to make drugs more affordable especially for older americans. stuart: many thanks. jason alldean under attack over his new country song. we have the response to the critics coming up. prince harry and meghan markel's one hundred million dollar netflix deal is in trouble because of the hollywood strike. neil sean has details and joins me next. ♪ at t. rowe price our strategic investing approach can help you build the future you imagine. t. rowe price, invest with confidence. this is spring semester at fairfield-suisun unified. they switched to google tools for education because there's never been a reported ransomware attack on a chromebook. now they're focused on learning knowing that their data is secure. ( ♪ ) we planned well for retirement, but i wish we had more cash. you think those two have any idea? that they can sell their life insurance policy for cash? so they're basically sitting on a goldmine? i don't think they hav

take >> i asked that question and you think of bristol myers >> yes, because brissetol myerss what people used to like people are liking industrials that can shoot the lights out. they're liking tech that is software enterprise that is no longer spending like a, you know, crazy sailors. they like oils that are not spending like crazy sailors. they like financials now that they have been brought down to a level where they can be bought they like costco because it's a group for the consumer and basically, what they like is anything in the nas. >> yeah. 37% is the gain on the nasdaq. >> buy microsoft amy hood has been -- >> 20% gain. it's been a good year, to say the least, for our broad markets >> abvi had a good quarter so far. >> that's good to know, jim. thank you. before we head to break, let's give you a look at the bond market as well we're a day out from the fed raising rates by 25 basis points key question, of course, continues to be, what's next higher for longer? is that possible if you see the two-year at 4.891% and the ten, 3.905% we're back eiright after this we pla

might have a more realized valuation, do you think, there is a catch-up trade now in good old bristol-myershat concludes the lightning round. >> the lightning round is sponsored by tdm imagery. >> operator, give me any major ceo. every earnings call tells a story but they are not happy for all of them. kramer explains next. u want t ue on this one. [inaudible] wow! yeah! it's time to take control of your investing education. cut through the noise with best-in-class education resources that match your preferred style of learning. learn your way. not theirs. td ameritrade. where smart investors get smarter℠. oppenheimer is magnificent. the new york times calls it t staggering.. it's utterly enthralling and one of the best movies of the century. >>> i say the same thing every earnings season. before you react, wait until the end of the call. listen to the call. read the transcript. if you know how to interpret it, you will know whether to buy or sell. it is not always easy. many calls can fool you. we caught that last night. expanding everything was great. cannot have been more wrong. i'm seei

this is a very attractively priced fpharmaceutical/biotech this is not like bristol-myers or somethingf these nose bleed biotechs, either so appropriately priced. >> cathy from chicago bought gilead sciences at $65 and $75 buy, sell, hold? >> it's a good buy she should hold the position, maintain the long. reasonable valuation at 12 times. i believe gilead, along with intuitive surgical, will be a beneficiary of this upcoming july 24th nasdaq rebalance >> happy belated birthday. what's your view on the semiconductor sector for 2023 and beyond >> if you look at semis, they have benefitted from this ai craze and enthusiasm if you own semis, it's okay to let them keep running, especially if yields are coming down and we continue to see optimism in that industry group. however, if we get an indication that there is a contraction to come or a pullback in the market, that's when we row tate out and go into something like financials or energy >>> coming up, "final trades." stayitus wh clashing) -had enough? -no... arthritis. here. aspercreme arthritis. full prescription-strength? reduces infl

kevin's point and where i totally agree you look at these pharmaceuticals companies, and i own bristol-myersnd abvie, the population that will promote use of drugs tells me this is where you want to be i'm also in cvs. hasn't done very well. i still look at unh, steve, and i look at that multiple and i'm really not sure why cvs has a multiple less than half of unh you can come up with reasons but the transformative acquisitions cvs is making i'm very happy there. >> vertex, too >> a biotech it's a smaller position for me it's not that expensive relative to a lot of the biotechs that generally populate the xvi >> the market is close to session highs. up next, mike santoli will join us with his "midday word." the dow firmly in positive territory right now. we'll talk a lot more about that when "halftime" comes back 5g, t, and unlimited hotspot data. so, no matter what, i'm running this kitchen. (vo) make the switch. it's your business. it's your verizon. >>> welcome back mike santoli joins us now with his midday word. mike >> you know, frank, it feels like this market all year, you've needed s

moving on, bristol-myers, they're down 2.5%.ons like their blood cancer treatment and their blood thinner. they also expect their full-year revenue to fall as a result, so their outlook, not positive. stuart: southwest airlines. lauren: you know, record revenue in the quarter, just over $7 billion. record revenue. travel boom. why is the stock down 8.5 percent? if there's the one metric, we spoke about this, it's called revenue per available seat mile. they think it's going to fall in the third quarter. so this travel boom, yeah, it's still a boom, but it's slowing down. and when you're looking at a company like southwest, our largest domestic carrier, maybe they're going to suffer a little bit. they can't bring in as much money. they're paying more in labor. think of all the strikes by pilots, the flight attendants and the kansas cost of jet fuel. -- cost of jet fuel. stuart: jet fuel is going up. oil is up, gasoline has gone up 12 cents in a week, i have to believe jet fuel is up as well. probably we'll see the oil companies g

closely in some cases, not this one, that there's plenty of competition amongst the pfizers, merck, bristol myers and on from there. glaxo. for these very companies that are at the forefront of innovating, but when they get to that point where they've hit commercialization, they don't have the sales forces. they don't have the ability to bring the thing to market in an effective way, and that's the plan do some really great science, get them to phase two, maybe phase three, and then sell to big pharma, a la what they're doing with reata >> they're issuing long-term debt in this market to buy the company at a significant premium, which you really don't hear about much these days they're using cash on hand, a combination of cash on hand and financing in the markets to do this and so, you've got the regulatory uncertainty financing may be less of an uncertainty. you know, big deals are hard to come by this year. and last year. >> they are. i am hearing generally a lot more conversation. i think i've said this a number of times from the m&a professionals that i tend to speak to, which is somewhat of